In order to narrow the gap between bench-and-bedside, our study raised the following question: will celecoxib still preserve its antitumor capabilities in lower concentrations (IC50 in nM range), enhance the melanoma therapeutic response and block AKT resistance pathway activation? This evidence concerns the gene AKT1 and melanoma.